高通量查用于在现实世界 ангиотензин转化酶抑制剂发起者之间处方级联.
Asinamai M Ndai1,2,3, Kayla Smith1,2,3, Shailina Keshwani1,2,3
1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Pharmacoepidemiology and drug safety
|March 18, 2025
概括
ангиотензин转化酶抑制剂 (ACEI) 的副作用可能导致处方级联. 这项研究在医疗保险受益者中确定了潜在的ACEI诱导的处方级联,突出了诸如皮质类固醇和交感类药物使用等风险.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 医疗保健服务研究 医疗服务研究
背景情况:
- ангиотензин转化酶抑制剂 (ACEI) 是被广泛使用的抗高血压药物.
- 与ACEI相关的不良药物事件可能导致新药的开始,这种现象被称为处方级联 (PC).
- 识别ACEI诱导的PC对于改善患者安全和优化药物管理至关重要.
研究的目的:
- 为了确定由 ангиотензин转化酶抑制剂 (ACEI) 启动的潜在处方级联.
- 利用高通量序列对称性分析来检测这些药物诱导的处方模式.
- 评估确定的ACEI诱导PC的临床可信性和量化风险.
主要方法:
- 对2011-2020年国家医疗保险索赔数据的分析,针对66岁及以上的受益人.
- 在ACEI开始后90天内对446种非抗高血压药物类别的启动进行查.
- 对显著信号进行调整的序列比率 (aSRs) 和自然化伤害必要数 (NNTH) 的计算,然后进行临床审查.
主要成果:
- 分析了超过308,000个ACEI发起者.
- 检测到81个显著信号,其中42个在临床审查后被归类为潜在的ACEI诱导的处方级联.
- 最强的信号包括皮质类固醇 (NNTH 313) 和血清素5-HT3抗剂 (NNTH 496),以及交感模拟剂 (aSR 1.97).
结论:
- 该研究确定了与已知和可能未被认可的ACEI不良事件相关的潜在处方级联.
- 这些发现表明,ACEI的使用可能有助于随后对其他药物类别的处方.
- 需要进一步的研究来证实这些已识别的处方级联对患者结果的程度和临床影响.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
466
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
436
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
436
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
561
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
561
01:26Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K